Miguel Regueiro, MD
A Miss for FMT in Ulcerative Colitis, Additional Upadacitinib Benefits in Crohn’s
This month’s report looks at two distinct issues: fecal microbiota transplantation and upadacitinib.
SEPTEMBER 27, 2024
FDA Approves Guselkumab for UC
The FDA has approved Tremfya for patients with moderately to severely active ulcerative colitis.
SEPTEMBER 12, 2024
Postoperative Considerations in IBD
This month, we look at two examples of how to manage postoperative inflammatory bowel disease.
MARCH 25, 2024
Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk
In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...
JANUARY 1, 2024
Racial Disparities Seen in Use of IBD Medical Therapy
Black patients with IBD are less likely to be treated with certain therapies than white IBD patients, according to ...
JANUARY 17, 2023
